3Pfaller MA,Diekema DJ.Twelve years of fluconazole in clinical practice:global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida[J].Clin Microbiol Infect,2004,10 (Suppl 1):11-23.
4Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis[J].Clin Infect Dis,2004,38:161-189.
5Sanz-Rodriguez C,Lopez-Duarte M,Jurado M,et al.Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections[J].Bone Marrow Transplant,2004,34(1):13-20.
6Mora-Duarte J,Betts R,Rotstein C,et al.Comparison of caspofungin and amphotericin B for invasive candidiasis[J].N Engl J Med,2002,347:2020-2029.
7Krause DS,Reinhardt J,Vazquez JA,et al.Phase 2,randomized,dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia[J].Antimicrob Agents Chemother,2004,48:2021-2024.
8Bowden R,Chandrasekar P,White MH,et al.A double-blind,randomized,controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients[J].Clin Infect Dis,2002,35:359-366.
9Ellis M,Spence D,de Pauw B,et al.An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis[J].Clin Infect Dis,1998,27:1406-1412.
10Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347:408-415.
